blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1



Saturday 4 December 2010

Paxil / Seroxat - Dismissal Granted in Paxil birth defect case Case - but don't expect Bob to tell you !!

Dismissal Granted in Paxil Case


Anna Blyth's case against GlaxoSmithKline, the makers of the popular antidepressant drug Paxil, has been dismissed by a Philadelphia judge.

http://www.productliabilityattorneyblog.com/2010/11/dismissal_granted_in_paxil_cas.html

In the case, Blyth alleged that taking Paxil during her pregnancy caused her now 14-year-old daughter Anna to be born with specific cardiac birth defects. Part of Glaxo's defense strategy was to state that while unfortunate, 3-5 percent of all live births today are to children with birth defects. They also stated that this happens with and without the mother having taken medications during the pregnancy.  



Glaxo officials have stated before that they don't think they did anything wrong in how they researched and studied Paxil. This includes how they shared the information that these studies produced with various regulators like the FDA. Glaxo claims that after Paxil had been granted approval from the FDA for use, the company acted correctly when marketing the prescription medication. This included how Glaxo monitored its safety, and how it updated the information on how it is used during pregnancy.



All of the information on Paxil's label was said by Glaxo to be new information that was available at the time. The company said that it put everything on the labels as soon as new information was made available. Glaxo officials also say they submitted all new data to regulators, the public and the medical community. For these reasons, the company believes it should not be held liable for Anna's birth defects.



The judge in this case apparently agreed with Glaxo and granted the dismissal. This case is cause for Glaxo to celebrate big time since it has lost or settled many of its recent lawsuits and has been forced to pay more than $1 billion in settlements and fees. But the jury remains out on whether this case will set the precedence for future birth defects cases against Glaxo since the Blyth case is the first of its kind to come to trial.



Posted by Carey, Danis & Lowe, L.L.C.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.